Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 61

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 61
---
 Neuropathy      Japan         Filed (Aug 2024) 2   
  TAK-880                                                            Immunoglobulin (10%) [human] (injection) (Low IgA)                                            Biologic and other      Primary Immunodeficiencies                                                                     EU            Approved (May 2025)  
  TAK-961                                                            Immunoglobulin (10%) [human] (injection)                                                      Biologic and other      Multiple Indications                                                                           Japan         Filed (Feb 2025)     
                                                                     Immunoglobulin (5%) [human] (injection)                                                       Biologic and other      Autoimmune Encephalitis (AE)                                                                   Japan         P-III                
  TAK-330                                                            Four-factor prothrombin complex concentrate [human] (injection)                               Biologic and other      Coagulation Disorder, Direct Oral Anticoagulants (DOAC) reversal in surgical situations        U. S.         P-III                
  TAK-881                                                            Immunoglobulin (20%) [human] + recombinant hyaluronidase replacement therapy (injection)      Biologic and other      Primary Immunodeficiencies                                                                     U. S.         P-III                

____________

Note:

(1) Partnership with Halozyme.

(2) In June 2025, Takeda announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved a partial change to the manufacturing and marketing authorization for these indications.

Table of Contents

Vaccines

In Vaccines, Takeda is applying innovation to tackle some of the world’s most challenging infectious diseases such as dengue (QDENGA), and COVID-19 (NUVAXOVID). To support the expansion of our pipeline and the development of our programs, we have entered into partnerships with government organizations in Japan and leading global institutions including WHO (World Health Organization), PAHO (Pan American Health Organization) and Gavi (Global Alliance for Vaccines and Immunization), among others. These partnerships have been essential in building the critical capabilities that will be necessary to deliver on our programs and realize their full potential.

Our vaccines pipeline in clinical development as of May 8, 2025 (the date of our annual earnings release), along with notes for major subsequent developments thereafter, is as follows:

  Development code                       Type of Vaccine                                                             Modality                Indications / additional formulations                                                                                             Country/      Stage                
  TAK-019 1                              Recombinant coronavirus (SARS-CoV-